. 2018 Mar-Apr;44(2):93–98. doi: 10.1590/S1806-37562016000000378

Table 3. Treatment regimens used and patient outcomes observed, by study group. Belém, Brazil, 2015.

Variable	Group^a		p*	OR (95% CI)
Variable	MABSC (n = 17)	NTM (n = 26)	p*	OR (95% CI)
Regimen used^b
1st regimen	6 (35.3)	20 (91.0)^‡		1.0
2nd regimen	7 (41.2)^†	2 (9.0)	0.0007	11.70 (1.9-71.8)
3rd regimen	4 (23.5)^†	0 (0.0)		-
Primary outcome^c (after 1st regimen)
Clinical improvement and cure	3 (17.6)	20 (83.2)^†	< 0.0001	1.00
Dropout	3 (17.6)	2 (8.4)		10.00 (1.2-86.9)
Treatment failure	11 (64.8)^†	2 (8.4)		36.70 (5.3-253.8)
Secondary outcome
Clinical improvement and cure	10 (91.0)	2 (100)	0.3917	1.0
Death	1 (9.0)	0 (0.0)	0.3917	-

MABSC: Mycobacterium abscessus complex; NTM: mycobacteria other than M. tuberculosis mycobacteria and MABSC; 1st regimen: rifampin, ethambutol, and clarithromycin; 2nd regimen: 1st regimen plus amikacin or streptomycin; and 3rd regimen: 2nd regimen plus imipenem. ^aValues expressed as n (%). ^bThe value of n is different in the NTM group because of two deaths and two dropouts for which there was no information on primary outcome. ^cThe value of n is different in the NTM group because of two deaths of unknown cause. *G-test and analysis of adjusted residuals, when necessary. ^†Cell with statistical significance.